

PERIHILAR BILE DUCTS STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS		PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i>
☐ y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	TUMOR SIZE: _____	LATERALITY: ☐ left ☐ right ☐ bilateral	☐ y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery
☐ TX ☐ T0 ☐ Tis ☐ T1 ☐ T2a ☐ T2b ☐ T3 ☐ T4	PRIMARY TUMOR (T) Primary tumor cannot be assessed No evidence of primary tumor Carcinoma <i>in situ</i> Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue Tumor invades beyond the wall of the bile duct to surrounding adipose tissue Tumor invades adjacent hepatic parenchyma Tumor invades unilateral branches of the portal vein or hepatic artery Tumor invades main portal vein or its branches bilaterally; or the common hepatic artery; or the second-order biliary radicals bilaterally; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement		☐ TX ☐ T0 ☐ Tis ☐ T1 ☐ T2a ☐ T2b ☐ T3 ☐ T4
☐ NX ☐ N0 ☐ N1 ☐ N2	REGIONAL LYMPH NODES (N) Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis (including nodes along the cystic duct, common bile duct, hepatic artery, and portal vein) Metastasis to periaortic, pericaval, superior mesentery artery, and/or celiac artery lymph nodes		☐ NX ☐ N0 ☐ N1 ☐ N2
☐ M0 ☐ M1	DISTANT METASTASIS (M) No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis		☐ M1
ANATOMIC STAGE • PROGNOSTIC GROUPS			
CLINICAL		PATHOLOGIC	
GROUP T N M	☐ 0 Tis N0 M0 ☐ I T1 N0 M0 ☐ II T2a-b N0 M0 ☐ IIIA T3 N0 M0 ☐ IIIB T1-3 N1 M0 ☐ IVA T4 N0-1 M0 ☐ IVB Any T N2 M0 Any T Any N M1	GROUP T N M	☐ 0 Tis N0 M0 ☐ I T1 N0 M0 ☐ II T2a-b N0 M0 ☐ IIIA T3 N0 M0 ☐ IIIB T1-3 N1 M0 ☐ IVA T4 N0-1 M0 ☐ IVB Any T N2 M0 Any T Any N M1
☐ Stage unknown		☐ Stage unknown	

HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION

(continued on next page)

PERIHILAR BILE DUCTS STAGING FORM

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)

REQUIRED FOR STAGING: None

CLINICALLY SIGNIFICANT:

Tumor location _____

Papillary variant _____

Tumor growth pattern _____

Primary sclerosing cholangitis _____

CA 19-9 _____

Carcinoembryonic antigen (CEA) _____

General Notes:

For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

a prefix designates the stage determined at autopsy: aTNM.

surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

Histologic Grade (G) (also known as overall grade)

Grading system

☐ 2 grade system

☐ 3 grade system

☐ 4 grade system

☐ No 2, 3, or 4 grade system is available

Grade

☐ Grade I or 1

☐ Grade II or 2

☐ Grade III or 3

☐ Grade IV or 4

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

☐ Lymph-Vascular Invasion Not Present (absent)/Not Identified

☐ Lymph-Vascular Invasion Present/Identified

☐ Not Applicable

☐ Unknown/Indeterminate

Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

☐ RX Presence of residual tumor cannot be assessed

☐ R0 No residual tumor

☐ R1 Microscopic residual tumor

☐ R2 Macroscopic residual tumor

☐ Clinical stage was used in treatment planning (describe): _____

☐ National guidelines were used in treatment planning ☐ NCCN ☐ Other (describe): _____

Physician signature

Date/Time

HOSPITAL NAME/ADDRESS


PATIENT NAME/INFORMATION

(continued from previous page)

PERIHILAR BILE DUCTS STAGING FORM

Illustration

Indicate on diagram primary tumor and regional nodes involved.



HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION